AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20854662
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg s.c. biweekly)
Trial: 19016147
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (group 2)
Trial: 10781640
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (n=15)
Trial: 10781640
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg simvastatin (n=15)
Trial: 10781640
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n=15)
Trial: 8782136
Drug: Intraarticular local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular local anesthetic (bupivacaine 0.25%, 5 ml)
Trial: 2937131
Drug: Intramuscular medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular medroxyprogesterone acetate (MPA) 500 mg/day for at least two months after the operation
Trial: 2937131
Drug: MPA 500
RxNorm normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA 500 mg/3 times a week for one year
Trial: 29846031
Drug: Pharmacy-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy-based intervention including medication review, regular dose dispensing, and counselling regarding medication use and symptoms of heart failure.
Trial: 26916877
Drug: Daily Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily Teriparatide (TPTD)
Trial: 18687376
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor (DRD2) 957C>T polymorphism
Trial: 7759412
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of ketoprofen
Trial: 232024
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitors SQ 20881 and captopril
Trial: 26248655
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (InGaAlP laser, 650 nm, 100 mW, 2 J per point, applied from the first day of conditioning until D + 5)
Trial: 26248655
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (simulated laser treatment)
Trial: 21586498
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for 30 min each morning for 11 days
Trial: 15901744
Drug: Eniporide (2.5-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eniporide (2.5-400 mg)
Trial: 15772362
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (IT)
Trial: 6351027
Drug: Erythrityl tetranitrate
RxNorm normalized name: Erythrityl tetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrityl tetranitrate (ETN) 5 mg
Trial: 30616791
Drug: Primary radiotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiotherapy with concurrent chemotherapy (CRT)
Trial: 30616791
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with definitive RT
Trial: 28471697
Drug: Pirfenidone 2,403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone 2,403 mg/d
Trial: 20137430
Drug: Levofloxacin sensitivity
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin sensitivity (G(+)C)
Trial: 20137430
Drug: Levofloxacin sensitivity
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin sensitivity (G(-)B)
Trial: 17725542
Drug: ALA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA group (20 mg/kg body weight of 5-aminolevulinic acid)
Trial: 10975044
Drug: Multi-injection protocol
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-injection protocol for correcting postprandial blood glucose
Trial: 8869411
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (50 ml/kg for 1 h) in acute study
Trial: 1948810
Drug: RU 28318
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 28318 (160 mg)
Trial: 1948810
Drug: Spironolactone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (80 mg)
Trial: 29403268
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine
Trial: 29403268
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline
Trial: 29403268
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 2% lidocaine and 2 mL normal saline
Trial: 21833684
Drug: Glenohumeral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenohumeral steroid injections (Group B)
Trial: 20587725
Drug: Hypoglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (blood glucose 2.5 mmol/l) in nondiabetic participants
Trial: 20587725
Drug: Hypoglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (blood glucose 2.5 mmol/l) in type 1 diabetes
Trial: 16122457
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and aspirin (both)
Trial: 16122457
Drug: Aspirin only
RxNorm normalized name: Aspirin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin only (n = 598)
Trial: 16122457
Drug: Neither medication
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither medication (n = 236)
Trial: 8890804
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of dipyridamole
Trial: 1985721
Drug: VAP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAP chemotherapy (vincristine, doxorubicin, and prednisone) with radiotherapy for local relapse
Trial: 1985721
Drug: Triple-drug intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug intrathecal therapy and regimens of 6-thioguanine and cytarabine alternating with vincristine, prednisone, cyclophosphamide, and cytarabine
Trial: 1985721
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for testicular relapse
Trial: 6368649
Drug: Continuous ASA
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ASA treatment
Trial: 6368649
Drug: Desensitization to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization to ASA followed by ASA treatment
Trial: 29952408
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous propofol anaesthesia (TIVA), n = 31
Trial: 26473667
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) 30 mg BID + Asunaprevir (ASV) 200 mg BID + Beclabuvir (BCV) 150 mg BID
Trial: 20374607
Drug: 6-monthly cytological
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly cytological screening in primary care
Trial: 16926382
Drug: Maximal ADP
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal ADP stimulated respiration with FA-derived substrate (palmitoyl-l-carnitine + malate)
Trial: 14964744
Drug: efalizumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efalizumab 1.0 mg/kg/wk
Trial: 3898805
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g brewer's yeast
Trial: 22290273
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg daily for 21 days followed by single-dose ridaforolimus 40 mg on day 14
Trial: 22290273
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg daily for 14 days followed by single-dose ridaforolimus 2 mg on day 2
Trial: 16022174
Drug: Coumadin Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumadin Aspirin Reinfarction Study
Trial: 10434166
Drug: Theophylline administration
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline administration (6 mg kg‐1 infused over 7.5 min)
Trial: 7607766
Drug: celiprolol 200‐400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol 200‐400 mg/day
Trial: 7607766
Drug: metoprolol 100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 100‐200 mg/day
Trial: 2094056
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone substitution and Cavinton adjuvant therapy
Trial: 2094056
Drug: Hormone substitution
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone substitution therapy
Trial: 27077693
Drug: STAND (Supporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAND (Supporting Teens' Autonomy Daily)
Trial: 15766366
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) b.i.d. for 3 months
Trial: 14670773
Drug: Recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant growth hormone (rGH) treatment, 1 IU/kg/week, administered via daily subcutaneous injections for 12 months.
Trial: 8880055
Drug: Citalopram (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10, 20, 40, 80 mg)
Trial: 8880055
Drug: Fluoxetine (3-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (3-week intervals)
Trial: 8880055
Drug: Fluvoxamine (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (25, 50, 100, 200 mg)
Trial: 8880055
Drug: Paroxetine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10, 20, 40, 80 mg)
Trial: 6347173
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (antacid and placebo)
Trial: 30459575
Drug: Intramuscular Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular Electrical Stimulation (EIMS) at 2 Hz for ten sessions
Trial: 30459575
Drug: Intramuscular Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular Electrical Stimulation (EIMS)
Trial: 16238217
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Trial: 16238217
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) cavity preparations using encapsulated Fuji IX GP and Ketac-Molar
Trial: 12404887
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dequalinium chloride, treated once per day for 6 days
Trial: 12404887
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg povidone iodine, treated once per day for 6 days
Trial: 9593495
Drug: Selective dorsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective dorsal rhizotomy (SDR) and therapy (PT and OT)
Trial: 9593495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) receiving physiotherapy (PT) and occupational therapy (OT)
Trial: 2963509
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone premedication
Trial: 30721201
Drug: Traditional neuroprotective
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional neuroprotective therapy
Trial: 24622716
Drug: SYR-472 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 12.5 mg
Trial: 24622716
Drug: SYR-472 25
RxNorm normalized name: petrolatum 0.472 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 25 mg
Trial: 24622716
Drug: SYR-472 50
RxNorm normalized name: petrolatum 0.472 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 50 mg
Trial: 24622716
Drug: SYR-472 100
RxNorm normalized name: petrolatum 0.472 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 100 mg
Trial: 24622716
Drug: SYR-472 200
RxNorm normalized name: petrolatum 0.472 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 200 mg
Trial: 23011525
Drug: Monotherapy (valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (valsartan or amlodipine)
Trial: 23011525
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (including hydrochlorothiazide)
Trial: 23011525
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy controlled vs uncontrolled
Trial: 17350216
Drug: Lipo-ecraprost (60-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo-ecraprost (60-microg dose administered intravenously starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Trial: 17350216
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Trial: 12490752
Drug: Study care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study care protocol (no-rinse skin cleanser after each episode and application of a barrier cream with durable properties after the first incontinence episode of each shift)
Trial: 12490752
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care regimen (soap and water cleansing after each incontinence episode, followed by application of a moisturizing lotion)
Trial: 8013758
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg per os, at -5 and -1 h before the clamp)
Trial: 2786673
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g six times per day via gastric tube)
Trial: 2786673
Drug: Ranitidine (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (six 50‐mg to six 100‐mg doses per day intravenously)
Trial: 5354877
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt) at 55 mug
Trial: 5354877
Drug: Isoprenaline sulphate
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline sulphate inhalation at 550 mug
Trial: 5354877
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE(1)) inhalation (free acid or neutral triethanolamine salt)
Trial: 5354877
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt)
Trial: 31448013
Drug: Daily follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily follow-up reminder
Trial: 31448013
Drug: Incentivised mHealth
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentivised mHealth solution
Trial: 28735755
Drug: 30min of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30min of vigorous‐intensity exercise 24h prior to the first doxorubicin treatment
Trial: 28735755
Drug: No vigorous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vigorous exercise for 72h prior to treatment (control)
Trial: 25896256
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine challenge during a 55-minute resting-state scan
Trial: 24379055
Drug: Fixed oral
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed oral combination of hyaluronic acid and chondroitin-sulphate (HA+CS)
Trial: 21457209
Drug: Adapalene-benzoyl peroxide
RxNorm normalized name: Adapalene-Benzoyl Peroxide Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene-benzoyl peroxide gel
Trial: 8093148
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional oral education at outpatient or surgery visits)
Trial: 28826348
Drug: Tablet computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer-based intervention
Trial: 10357732
Drug: Phytosterol-enriched diet
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol-enriched diet (1.7 g phytosterols/d for 30 d)
Trial: 8952863
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin administration with tissue plasminogen activator
Trial: 8952863
Drug: Subcutaneous or
RxNorm normalized name: Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous or intravenous heparin use with streptokinase
Trial: 6125205
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine 200 mg or 400 mg
Trial: 6125205
Drug: Capsule preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule preparations of diazepam
Trial: 26599796
Drug: Saline flush
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline flush (20 mL normal saline) after rocuronium administration
Trial: 24271264
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (CT, n = 61)
Trial: 20400266
Drug: Quebec Back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quebec Back Pain Disability Scale (administered pre-treatment and post-treatment)
Trial: 15529306
Drug: Low‐radiation dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐radiation dose spiral computed tomography (LDCT)
Trial: 10499652
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (n = 10): standard heparinization (300 IU/kg) plus two doses of purified antithrombin III (1000 IU each)
Trial: 10499652
Drug: Group GA
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group GA (n = 10): 200 IU/kg heparin, continuous infusion of heparin (100 IU/kg/h) and gabexate mesilate (2 mg/kg/h) plus the same dose of antithrombin III as group A
Trial: 6818588
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg nicotine cigarettes
Trial: 6818588
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg nicotine cigarettes
Trial: 29089063
Drug: Lotilaner (Credelio™,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™, Elanco) at 20 mg/kg
Trial: 29089063
Drug: Afoxolaner (Nexgard®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afoxolaner (Nexgard®, Merial) at 2.5 mg/kg
Trial: 26981577
Drug: Oral phage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phage therapy (T4-like coliphages or commercial Russian coliphage product)
Trial: 26981577
Drug: Oral phage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phage therapy
Trial: 25066269
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg, intravenous) with mFOLFOX6
Trial: 25066269
Drug: Low-dose linifanib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose linifanib (7.5 mg) with mFOLFOX6
Trial: 25066269
Drug: High-dose linifanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose linifanib (12.5 mg) with mFOLFOX6